Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes

ABSTRACT Aims To evaluate characteristics and glycemic outcomes in individuals with type 2 diabetes using injectable therapies in real‐world clinical practice in Tianjin, China. Materials and methods Data from inpatients and outpatients receiving injectable therapies between January 2015 and Decembe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qiumei Zhang, Yaqing Fan, Xixi Liu, Minlu Zhang, Jiewen Zhang, Qin Du, Lei Kang, Liming Chen
Format:	Article
Language:	English
Published:	Wiley 2025-05-01
Series:	Journal of Diabetes Investigation
Subjects:	Glucagon‐like peptide‐1 receptor agonists Hypoglycemic agents Insulins
Online Access:	https://doi.org/10.1111/jdi.14415
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

Semaglutide and the Retina
by: Zachary T. Bloomgarden
Published: (2025-04-01)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes
by: Graciela Zambrano-Galván, et al.
Published: (2024-10-01)

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
by: Cheney C, et al.
Published: (2025-05-01)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017-08-01)

Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
by: Dariush Mozaffarian, et al.
Published: (2025-09-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Obesity and heart failure with preserved ejection fraction: focus on new drugs and future direction in medical treatment
by: Se-Eun Kim, et al.
Published: (2025-05-01)

A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide
by: Laura Patton, et al.
Published: (2025-07-01)

Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease
by: Melinda Urkon, et al.
Published: (2025-04-01)

Semaglutide in people with obesity and type 2 diabetes on hemodialysis: a prospective analysis of glycemic and weight outcomes
by: Akinori Hayashi, et al.
Published: (2025-05-01)

GLP-1 and Its Role in Glycogen Production: A Narrative Review
by: Joseph Lotosky, et al.
Published: (2025-06-01)

Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
by: Joon Seok Park, et al.
Published: (2025-05-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Characterization of treatment intensified (add‐on to metformin) adults with type 2 diabetes in Thailand: A cross‐sectional real‐world study (CONVERGE)
by: Chutintorn Sriphrapradang, et al.
Published: (2025-06-01)

Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational
by: Olga P. Kovtun, et al.
Published: (2025-05-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes
by: Anna A Mosikian, et al.
Published: (2022-03-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature
by: Yuki Taki, et al.
Published: (2025-04-01)

Research progress on the effect of type 2 diabetes and hypoglycemic drugs on the prognosis of patients with colorectal cancer
by: ZHANG Meng，LEI Xuefen，CHEN Haixia，CHEN Yixuan，JIANG Li
Published: (2025-07-01)

Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01)

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait
by: Saleh Alali, et al.
Published: (2025-05-01)

Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
by: Zhixuan Xie, et al.
Published: (2025-07-01)

The hidden impact of GLP‐1 receptor agonists on endometrial receptivity and implantation
by: Alberto Sola‐Leyva, et al.
Published: (2025-02-01)

Glucagon-like peptide-1 receptor agonist use is associated with reduced risk of out-of-hospital cardiac arrest in women with type 2 diabetes: A nationwide nested case-control study
by: Talip E. Eroglu, et al.
Published: (2024-12-01)

Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis
by: Xiaoyu Ren, et al.
Published: (2025-07-01)

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
by: Yiwen Liu, et al.
Published: (2025-05-01)

Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence
by: Anqi Lin, et al.
Published: (2025-03-01)

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
by: Wael R. Sidrak, et al.
Published: (2024-11-01)

Pathology and Treatments of Alzheimer’s Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes
by: Hidekatsu Yanai, et al.
Published: (2024-12-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists therapy initiation in patients with type 2 diabetes hospitalized with coronavirus infection
by: T. N. Markova, et al.
Published: (2023-12-01)

Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025-06-01)

Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization
by: Xinyi Zhang, et al.
Published: (2025-05-01)

The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
by: Areesha Moiz, et al.
Published: (2025-08-01)

Investigation of potential relationship between glucagon-like peptide 1 receptor agonists with suicide/self-injury: disproportionality analysis using WHO-VigiBase
by: Ye Young Kim, et al.
Published: (2024-12-01)

Comparison of Effects of Glucagon-Like Peptide-1 Receptor Agonists Compared to Long-Acting Insulin, Added to Oral Anti-Diabetic Agents on Self-Management Behaviors, Anxiety, and Sleep Quality in Patients with Type 2 Diabetes
by: Song X, et al.
Published: (2025-03-01)

Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction
by: Yan H, et al.
Published: (2024-11-01)

Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
by: Yosra Turkistani
Published: (2025-04-01)